Clinical trial NCT06535503: Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City
Official title: Clinical Characteristics and Outcomes Among ST-elevation Myocardial Infarction (STEMI) Patients With Cardiogenic Shock at Abu Dhabi City
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: ST Elevation Myocardial Infarction
Cardiogenic Shock
Keywords: STEMI
Cardiogenic Shock
Morbidity
Mortality
Lead sponsor: Abu Dhabi Health Services Company
Sponsor class: OTHER_GOV
Collaborators: name: Sheikh Shakhbout Medical City
name: Sheikh Khalifa Medical City
First posted: 2024-08-02
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization were treated in Abu Dhabi city from January 2020 to January 2024.

Brief summary: A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024.

Detailed description: Cardiovascular disease (CVD) accounts for 40% of mortality in the UAE, which is higher than the global average. Long-term trends, incidence studies, and best practice guidance on Cardiogenic Shock (CS) with ST-elevation Myocardial infarction (STEMI) in the United Arab Emirates (UAE) and the Gulf Cooperation Council (GCC) are limited.

Through this retrospective study, investigators aim to identify treatment modalities and trends, hospitalization events, and patient demographics and comorbidities which lead to participant recovery or mortality in Sheikh Khalifa Medical City (SKMC) and Sheikh Shakhbout Medical City (SSMC) tertiary hospitals for patients admitted with STEMI and CS or developed CS after hospitalization with STEMI during January 2020-January 2024.\[200-400 participants\]. Data will be collected from eligible patients' electronic medical records (EMR).

Eligibility criteria: Inclusion Criteria:

* Age more than 18.
* STEMI complicated by cardiogenic shock.
* Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock.
* Patient admitted between January 2019 to March 2024.

Exclusion Criteria:

* Age less than 18.
* Shock patient not related to Myocardial infarction.
* NSTEMI-related cardiogenic shock.
* Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock.
* Patient not admitted between January 2019 to March 2024.

Primary outcomes:
measure: Analyze STEMI patient with CS disease profile
timeFrame: 5 years
measure: Incidence of CS-complicated AMI events
timeFrame: 5 years
measure: Analyze treatment outcomes in the targeted population as per the patient profile
timeFrame: 5 years
measure: Analyze STEMI patient with CS disease profile
timeFrame: 5 years
measure: Analyze treatment outcomes
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Abu Dhabi
country: United Arab Emirates
facility: Sheikh Khalifa Medical City (SKMC)
city: Abu Dhabi
country: United Arab Emirates
facility: Sheikh Shakhbout Medical City (SKMC)
Study officials:
affiliation: Abu Dhabi Health Services Co. -SEHA
name: Abdulmajeed BS Alzubaidi, MD
role: STUDY_CHAIR
affiliation: Sheikh Shakhbout Medical City
name: Babiker Babiker Mohamed Babiker Elsiraj MB Elsiraj
role: PRINCIPAL_INVESTIGATOR
References:
citation: Al-Shamsi S, Regmi D, Govender RD. Incidence of cardiovascular disease and its associated risk factors in at-risk men and women in the United Arab Emirates: a 9-year retrospective cohort study. BMC Cardiovasc Disord. 2019 Jun 17;19(1):148. doi: 10.1186/s12872-019-1131-2.
citation: Akbar H, Mountfort S. Acute ST-Segment Elevation Myocardial Infarction (STEMI). 2024 Oct 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK532281/
citation: De Luca L, Olivari Z, Farina A, Gonzini L, Lucci D, Di Chiara A, Casella G, Chiarella F, Boccanelli A, Di Pasquale G, De Servi S, Bovenzi FM, Gulizia MM, Savonitto S. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. Eur J Heart Fail. 2015 Nov;17(11):1124-32. doi: 10.1002/ejhf.339. Epub 2015 Sep 4.
citation: Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995 Sep;26(3):668-74. doi: 10.1016/0735-1097(95)00215-p.
citation: Shalaby G, Niazi AK, Khaled S. Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience. J Saudi Heart Assoc. 2023 Jan 20;34(4):232-240. doi: 10.37616/2212-5043.1323. eCollection 2022.
citation: Yusufali A, Bazargani N, Muhammed K, Gabroun A, AlMazrooei A, Agrawal A, Al-Mulla A, Hajat C, Baslaib F, Philip J, Gupta P, Bakir S, Krishnan S, Almahmeed W, Alsheikh-Ali A. Opportunistic Screening for CVD Risk Factors: The Dubai Shopping for Cardiovascular Risk Study (DISCOVERY). Glob Heart. 2015 Dec;10(4):265-72. doi: 10.1016/j.gheart.2015.04.008. Epub 2015 Aug 11.